Wayne Allard: “I would like to respond to this concern about drug companies investing relatively little and having huge returns. That…”

“I would like to respond to this concern about drug companies investing relatively little and having huge returns. That doesn't apply to every drug. Obviously, when you are developing a product for the market, there will be some that work out rather easily and the development costs may not be too much. But there are other drugs that require a substantial amount of work and analysis, and a considerable amount of thought has to go into the labeling. When those costs get high and when you hit those, the profit margin is not so large. I hate to see us pick out a few companies that may have had a windfall and then punish our children and say we are going to take away an incentive that has resulted in 80 percent of the children's drugs that have come to the market being approved and getting the proper licensing they require. In my view, we pick out a few outrageous circumstances and then we try and take away an incentive that has been working so well for us. My point, again, is why mess with that incentive when it is working so very well? As I had indicated here on the charts, we had such tremendous results in getting children's pediatric drugs to the market. This allows the pediatrician more choice in selecting therapies for their patients. It means better medicine. I also believe that the more products you have on the market, the more competition you have, and the more competition you have, that then holds down the price of drugs.”